U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C17H20N4S
Molecular Weight 312.432
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OLANZAPINE

SMILES

CN1CCN(CC1)C2=NC3=CC=CC=C3NC4=C2C=C(C)S4

InChI

InChIKey=KVWDHTXUZHCGIO-UHFFFAOYSA-N
InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3

HIDE SMILES / InChI
Molecular Formula C17H20N4S
Molecular Weight 312.432
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:13:50 UTC 2023
Edited
by admin
on Fri Dec 15 15:13:50 UTC 2023
Record UNII
N7U69T4SZR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OLANZAPINE
EMA EPAR   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
OLAZAX DISPERZI
Brand Name English
Olanzapine [WHO-DD]
Common Name English
OLAZAX
Brand Name English
OLANZAPINE [USP-RS]
Common Name English
OLANZAPINE [USP MONOGRAPH]
Common Name English
OLANZAPINE [VANDF]
Common Name English
SYMBYAX COMPONENT OLANZAPINE
Common Name English
LY-170053
Code English
OLANZAPINE CIPLA
Brand Name English
OLANZAPINE [USAN]
Common Name English
OLANZAPINE GLENMARK EUROPE
Brand Name English
OLANZAPINE [EP MONOGRAPH]
Common Name English
OLANZAPINE GLENMARK
Brand Name English
10H-THIENO(2,3-B)(1,5)BENZODIAZEPINE, 2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-
Systematic Name English
OLANZAPINE [ORANGE BOOK]
Common Name English
2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine
Systematic Name English
OLANZAPINE [MI]
Common Name English
ZYPREXA VELOTAB
Brand Name English
OLANZAPINE COMPONENT OF LYBALVI
Brand Name English
OLANZAPINE TEVA
Brand Name English
ZALASTA
Brand Name English
LYBALVI COMPONENT OLANZAPINE
Brand Name English
OLANSEK
Brand Name English
OLANZAPINE [EMA EPAR]
Common Name English
OLANZAPINE [MART.]
Common Name English
OLANZAPINE MYLAN
Brand Name English
olanzapine [INN]
Common Name English
LY170053
Code English
OLANZAPINE COMPONENT OF SYMBYAX
Common Name English
OLANZAPINE [JAN]
Common Name English
ZYPREXA
Brand Name English
OLANZAPINE APOTEX
Brand Name English
Classification Tree Code System Code
WHO-VATC QN05AH03
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLAZAX (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE TEVA (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLAZAX DISPERZI (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
WHO-ATC N05AH03
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE GLENMARK (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLAZAX (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE TEVA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZYPREXA VELOTAB (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
NCI_THESAURUS C29710
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZALASTA (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE MYLAN (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE GLENMARK EUROPE (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE GLENMARK EUROPE (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
LIVERTOX NBK548842
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
NDF-RT N0000175430
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZYPREXA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLAZAX DISPERZI (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE CIPLA (WITHDRAWN: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE CIPLA (WITHDRAWN: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE GLENMARK (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZYPREXA (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZYPREXA VELOTAB (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE MYLAN (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS ZALASTA (AUTHORIZED: SCHIOZPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANSEK (WITHDRAWN: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE APOTEX (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANZAPINE APOTEX (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
EMA ASSESSMENT REPORTS OLANSEK (WITHDRAWN: SCHIZOPHRENIA)
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
Code System Code Type Description
MERCK INDEX
m8184
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY Merck Index
PUBCHEM
135398745
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
INN
6956
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
EPA CompTox
DTXSID9023388
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
IUPHAR
47
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
SMS_ID
100000085471
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
NCI_THESAURUS
C47639
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
DAILYMED
N7U69T4SZR
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
DRUG CENTRAL
1982
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
CAS
132539-06-1
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
HSDB
8155
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
USAN
DD-64
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
CHEBI
7735
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
RXCUI
61381
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY RxNorm
RS_ITEM_NUM
1478301
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
EVMPD
SUB09426MIG
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
WIKIPEDIA
OLANZAPINE
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
DRUG BANK
DB00334
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
ChEMBL
CHEMBL715
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
LACTMED
Olanzapine
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
FDA UNII
N7U69T4SZR
Created by admin on Fri Dec 15 15:13:50 UTC 2023 , Edited by admin on Fri Dec 15 15:13:50 UTC 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 3A4
METABOLIC ENZYME -> SUBSTRATE
5-HYDROXYTRYPTAMINE RECEPTOR 2C
TRANSPORTER -> INHIBITOR
ANTAGONIST
IC50
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of OLANZAPINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of OLANZAPINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
Structure of OLANZAPINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
ALDEHYDE OXIDASE
METABOLIC ENZYME -> INHIBITOR
IC50
Structure of OLANZAPINE TARTRATE
SALT/SOLVATE -> PARENT
ALPHA-2A ADRENERGIC RECEPTOR
TARGET -> AGONIST
SHORT-ACTING
5-HYDROXYTRYPTAMINE RECEPTOR 2B
TARGET -> INHIBITOR
ANTAGONIST
IC50
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
5-HYDROXYTRYPTAMINE RECEPTOR 2A
TARGET -> INHIBITOR
ANTAGONIST
IC50
CYTOCHROME P450 1A2
METABOLIC ENZYME -> SUBSTRATE
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A4
METABOLIC ENZYME -> SUBSTRATE
FETAL HEPATIC FLAVIN-CONTAINING MONOOXYGENASE 3 (HUMAN)
METABOLIC ENZYME -> SUBSTRATE
Structure of OLANZAPINE PAMOATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of OLANZAPINE 4'-N-GLUCURONIDE
METABOLITE -> PARENT
URINE
Structure of N-DESMETHYLOLANZAPINE
METABOLITE -> PARENT
MINOR
PLASMA
Structure of LY-290411
METABOLITE -> PARENT
Structure of OLANZAPINE 10-N-GLUCURONIDE
METABOLITE -> PARENT
MAJOR
PLASMA; URINE
Structure of N-DESMETHYLOLANZAPINE
METABOLITE -> PARENT
lack pharmacological activity at the concentrations observed.
Related Record Type Details
Structure of N-CHLOROMETHYL OLANZAPINE CHLORIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LY-301664
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 5-METHYL-2-((2-NITROPHENYL)AMINO)-3-THIOPHENECARBONITRILE
IMPURITY -> PARENT
EP
Structure of 2-[(2-Aminophenyl)amino]-5-methyl-3-thiophenecarbonitrile
IMPURITY -> PARENT
Structure of 2-Amino-3-cyano-5-methylthiophene
IMPURITY -> PARENT
Structure of Olanzamine
IMPURITY -> PARENT
Structure of OLANZAPINE-N-OXIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of LY-301664
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-CHLOROMETHYL OLANZAPINE CHLORIDE
IMPURITY -> PARENT
if present
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 4,4′-(1,4-Piperazinediyl)bis[2-methyl-10H-thieno[2,3-b][1,5]benzodiazepine]
IMPURITY -> PARENT
Structure of 5-METHYL-2-((2-NITROPHENYL)AMINO)-3-THIOPHENECARBONITRILE
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Related Record Type Details
Structure of OLANZAPINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC Extensive
PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966